World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

OneChain Immunotherapeutics (OCI) has obtained authorisation for the CARxALL clinical trial to evaluate a new CAR-T therapy for patients who have T-cell leukaemia and no therapeutic alternatives. This clinical trial is the first of the developments being carried out by OCI, which was founded only two years ago.

OneChain Immunotherapeutics is a spin-off founded by the Josep Carreras Leukaemia Research Institute with investments from Invivo Ventures, CDTI-Innvierte (Ministry of Industry) and the Josep Carreras Foundation.

The CAR-T is directed against a new target CD1a. It has been developed in the laboratory of Dr. Pablo Menéndez, founder of the company OneChain Immunotherapeutics and principal researcher of the Josep Carreras Leukaemia Research Institute’s stem cell biology, developmental leukaemia and immunotherapy group. This Institute is directed by Dr. Manel Esteller.

The paediatric and adult patients to receive this treatment have a very poor prognosis, with a life expectancy of just a few months.

These patients will be treated at Hospital Sant Joan de Déu and Hospital Clínic Barcelona.

The clinical trial will include patients from Spain and across Europe, who will be treated in Barcelona.

Other CAR-T-based therapies have been shown to be highly effective in patients with haematological tumours.

The group led by Dr. Menéndez, founder of OCI and director of the Josep Carreras Institute’s stem cell biology, developmental leukaemia and immunotherapy group, was the first in the world to develop and validate a CD1a-specific CAR-T for coT-ALL. The study, led by Dr. Diego Sánchez and published in the journals Blood and the Journal for ImmunoTherapy of Cancer, has been conducted with animal models using cell lines derived from patients with coT-ALL. Preliminary results show that these CAR-T cells persist in vivo in the long term and retain their anti-leukaemia activity.

The CARxALL clinical trial represents another step towards developing adoptive cell immunotherapy, such as CAR–T cell therapy, a treatment that consists of extracting a patient’s T cells (cells that protect the body from infection), modifying them in the laboratory and returning them to the patient. This modification enables the cells to attack and eliminate the receptors located in the membranes of tumour cells. With this technique, the patient’s own modified cells attack the cancer cells in a directed way, without damaging healthy cells.

OCI achieved this important milestone after being created in 2020 through a round of seed capital amounting to 3.05 million euros provided by Invivo Ventures, CDTI-Innvierte and the Josep Carreras Foundation, and after receiving funding from the State Research Agency. This is a successful case of technology transfer and public-private collaboration involving recovery of public investment in research.

According to Dr. Menéndez, “Developing these strategies and managing all the regulatory mechanisms associated with developing a product is extremely complicated in the academic field. Therefore, OCI will enable us to carry out all the necessary steps to ensure that our knowledge benefits patients”.

Antoni Garcia Prat, the administrator of the Josep Carreras Foundation, added, “The Foundation decided to support the initial investment by Invivo Ventures and CDTI as an indication of its support for translational research and the research team. It is important to keep in mind that the projects concern rare or childhood haematological tumours, or those with few therapeutic alternatives, and that any profits generated for the Foundation will be fully invested in the fight against leukaemia, always in the best interests of patients”.

Prof. Evarist Feliu, president of the Josep Carreras Leukaemia Research Institute’s Delegate Committee, said, “Immunotherapy currently constitutes an important field for cancer treatment. Its main clinical relevance currently lies in immune system checkpoint inhibitors and adoptive therapy strategies with T cells, with more than 700 clinical trials taking place throughout the world for the treatment of malignant blood diseases and, to a lesser extent, solid tumours”.

Dr. Lluís Pareras and Albert Ferrer, founding partners of Invivo Ventures, went on to say, “OneChain is developing several programmes in the field CAR-T stemming from technology transfer. With its first programme, OCI has demonstrated its ability to bring a product based on academic research results to clinical trial in as little as two years. In addition, it has a new allogeneic platform, a haematological tumour programme and a solid tumour programme in the pipeline”.

 

Webpage updated 01/18/2023 13:55:56